Skip to main content
Glycorex Transplantation AB logo

Glycorex Transplantation AB — Investor Relations & Filings

Ticker · GTAB ISIN · SE0000524530 LEI · 549300BFHBYZ3X96EP25 NGM Manufacturing
Open in API
Filings indexed 98 across all filing types
Latest filing 2020-03-31 Regulatory Filings
Country SE Sweden
Listing NGM GTAB

About Glycorex Transplantation AB

https://glycorex.com/

Glycorex Transplantation AB is a medical technology company that has developed a proprietary technology platform for the specific removal of antibodies from blood. The technology is based on biologically active carbohydrates for extracorporeal blood treatment. Its flagship product, Glycosorb® ABO, is a single-use medical device that enables organ transplantation across the blood group barrier, primarily for kidney, liver, heart, and stem cell transplants. Used clinically since 2001, the product has facilitated over 6,000 ABO-incompatible transplants with documented long-term results comparable to blood group compatible procedures. The company is leveraging its core technology to expand into new applications, including a product for creating universal blood plasma for transfusions and developing novel treatments for autoimmune diseases, with an initial focus on rheumatoid arthritis.

Recent filings

Filing Released Lang Actions
Glycorex Transplantation (GTAB B): Bolagets UBP-produkt levererad till europeiskt sjukhus
Regulatory Filings Classification · 95% confidence The document is a press release from Glycorex Transplantation AB announcing the delivery of a medical product to a European hospital and providing an update on CE-marking progress. It is a short, news-oriented announcement regarding company operations and regulatory status, which does not fit into specific financial reporting categories like 10-K, IR, or ER. As it is a general corporate announcement required under the EU Market Abuse Regulation, it falls under the 'Regulatory Filings' (RNS) category.
2020-03-31 Swedish
Statusuppdatering med anledning av Coronaviruset
Regulatory Filings Classification · 95% confidence The document is a short corporate update regarding the impact of the Coronavirus on the company's operations and sales. It is under 5,000 characters and serves as a general regulatory announcement to the market regarding business status, rather than a formal financial report, presentation, or management report. As it does not fit into specific categories like earnings releases or dividend notices, it falls under the general regulatory filing category.
2020-03-12 Swedish
Major Shareholding Notification 2020
Major Shareholding Notification Classification · 100% confidence The document is a regulatory filing from the Swedish Financial Supervisory Authority (Finansinspektionen) regarding a 'flaggningsmeddelande' (flagging notification). This is a formal disclosure of a change in major shareholding (crossing a threshold) by a shareholder (Kurt Nilsson) in Glycorex Transplantation AB. This fits the definition of a Major Shareholding Notification (MRQ).
2020-03-04 Swedish
Glycorex Transplantation (GTAB B): Nytt antal aktier och röster
Share Issue/Capital Change Classification · 100% confidence The document announces a change in the total number of shares and votes for Glycorex Transplantation AB following a previously completed share emission. This type of disclosure, specifically regarding the change in share capital and voting rights, falls under the category of share issues or capital changes.
2020-02-28 Swedish
Interim / Quarterly Report 2019
Interim / Quarterly Report Classification · 95% confidence The document is a 'Bokslutskommuniké' (Year-end report) for Glycorex Transplantation AB for the period January-December 2019. It contains comprehensive financial statements (income statement, balance sheet, cash flow), management commentary, and operational updates. It is not a mere announcement (RPA) as it contains the full financial data and analysis for the fiscal year. In the context of financial reporting, a year-end report that includes full financial statements for the period is classified as an Interim/Quarterly Report (IR) if it is not the full audited Annual Report (10-K). FY 2019
2020-02-21 Swedish
Major Shareholding Notification 2020
Major Shareholding Notification Classification · 100% confidence The document is a 'flaggningsmeddelande' (flagging notification) filed with the Swedish Financial Supervisory Authority (Finansinspektionen). It details a change in shareholding and voting rights for a specific shareholder (Bill Nederman) in Glycorex Transplantation AB. This type of disclosure, where a shareholder notifies the regulator of crossing a threshold in ownership, is classified as a Major Shareholding Notification.
2020-01-30 Swedish

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.